NEWS 01.27.2026 Ernexa Therapeutics Selected for Japan Entry Acceleration Program to Advance Innovative Cell Therapies – Quiver Quantitative
NEWS 01.27.2026 Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II – BioSpace
NEWS 01.27.2026 Integrated Strategies in Meniscus Tissue Engineering: From Biomaterials to Stem Cell–Driven Regeneration – Frontiers
